13 August 2018
Visiongain’ has launched a new pharma report Brazilian Pharmaceutical Market Outlook 2017-2027: Originator, Generic, OTC, CNS, Cardiovascular, Gastrointestinal, Metabolic, Oncology, Infectious Diseases, Domestic Manufacturers and International Drug Companies
Brazil’s pharmaceutical market is the eighth largest in the world, and is growing at a faster rate than many of the markets in developed countries. Between 2005 and 2013 it experienced double digit growth rates, and the value of the market tripled. Despite current economic challenges, it is set to continue its expansion well into the 2020s, but at lower growth rates. Growth is being driven by a range of factors including a booming generic drugs market, an underlying shift towards chronic diseases, growing affluence in the country, and a government which aims to increase the population’s access to drugs by making numerous technology transfer deals with multinational companies.
The lead analyst of the report commented “While unmet medical needs present an important opportunity in many areas of the Brazilian market, the oncology and diabetes segments are particularly notable. Brazil has the fifth highest number of diabetes patients in the world while cancer has historically gone unaddressed by the healthcare system. SUS is now facilitating easier access to oncology drugs, thus there is an opportunity for growth.
The Brazilian government is pushing towards technology transfer. Technology transfer is likely to galvanise the nation’s domestic pharmaceutical industry as well as saving the SUS money, but it remains to be seen whether indigenous Brazilian companies will fulfil the government’s ambitions by becoming significant originators of pharmaceutical products and technology platforms.”
Leading companies featured in the report include Sanofi/Medley, EMS, Hypermarcas, Novartis, Eurofarma, Aché, Roche, Merck & Co., Pfizer, Takeda.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.
30 September 2020
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.